It is well to be noted that three-quarters of healthcare providers as well as pharmaceutical professionals go on to note that artificial intelligence-related techs are going to be widespread in the coming three years, as per a new survey from Berkeley Research Group, one of the consultancies.
But only around 40% of the surveyed professionals went on to say that organizations reviewed or even for that matter, planned to review the AI regulatory guidance.
Surveyed providers happened to be more optimistic, much more than the pharmaceutical professionals, that regulation could go on to provide the required guardrails for the usage of AI in healthcare. Industry stakeholders have gone on to raise their concerns that a too-rapid embrace of AI can very well go on to pose risks when it comes to data privacy as well as exacerbate inequities in health.
Generative AI has gone on to be a target of healthcare investment since the companies say the technology, which can go on to generate content such as text as well as images, happens to have the potential when it comes to improve diagnostic screenings and, at the same time, decrease the administrative load as far as clinicians are concerned.
AI investment has gone on to be steady even though other health markets went on to contract in 2023. The market size when it comes to healthcare AI happens to be projected to balloon from $28 billion this year to more than $180 billion by the end of the decade.
Apparently, there are concerns surrounding technology that have gone on to mount, thereby prompting the federal government to mull as to how to best regulate AI within healthcare.
According to Sen. Ron Wyden, it is indeed very clear that there is not enough is being done to safeguard the patients. He added that Congress now happens to have an obligation to make sure the good outcomes coming from AI set the rules for new innovations across American healthcare.
It is well to be noted that three-quarters of the provider respondents who have been surveyed by BRG said they went on to feel quite confident that future regulation as well as guidance could go on to impose guardrails on AI. More than 80% of the providers also went on to say that they felt pretty confident in their respective organizations as they could very well comply with potential regulations, considering that precision, safety, data privacy, as well as HIPAA violations were the top challenges. In contrast, 56% of pharmaceutical professionals happened to have the confidence in AI regulation.
Surveyed professionals were specifically concerned in terms of regulations with regards to data privacy, with more than 50% of the provider respondents stating that cybersecurity as well as data management happened to be their major concern.
Data privacy along with cybersecurity concerns have abounded since the number of healthcare breaches has risen. The federal government happens to be eyeing cybersecurity guidelines for this sector, and the Federal Trade Commission went so far as to levy fines in 2023 against GoodRx as well as BetterHelp for not disclosing personal health data.
Apparently, over four in ten provider respondents went on to say that AI has already gone on to be widely accepted as well as executed in their organizations, as per the survey. Providers go on to say that AI usage in diagnostics as well as imaging, preventative screenings, health predictions, and patient safety would significantly affect the industry. Administrative tasks such as revenue cycle management as well as supply chain management, could go on to be positively impacted.
It is well to be noted that the survey went on to poll 150 providers as well as pharmaceutical professionals.
